Skip to main content

Table 2 In the two groups were followed up for 1 and 3 months objective response

From: Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma

 

Treatment group

CR

PR

SD

PD

ORR(%)

X2

P

1 month

TACE-apatinib

0

18

6

3

18/27 (66.7)

5.236

0.020

TACE alone

0

21

18

14

21/53 (39.6)

  

3 months

TACE-apatinib

0

11

3

10

11/24 (45.8)

5.395

0.021

TACE alone

0

6

5

23

6/34 (17.6)

  
  1. Abbreviations: CR complete response, PR partial response, SD stable disease; PD progressive disease, ORR objective response rate, TACE transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us